Neurobiological Technologies Company Top Insiders
| NTII Stock | USD 0.0001 0.00 0.00% |
Neurobiological Technologies employs about 4 people. The company is managed by 2 executives with a total tenure of roughly 32 years, averaging almost 16.0 years of service per executive, having 2.0 employees per reported executive. Assessment of Neurobiological Technologies' management performance can provide insight into the firm performance.
| John Stuppin Chairman Founder, Director, Chairman of Nominating and Corporate Governance Committee and Member of Special Committee |
Neurobiological | Build AI portfolio with Neurobiological Stock |
Neurobiological Technologies Management Team Effectiveness
Neurobiological Technologies' management efficiency ratios could be used to measure how well Neurobiological Technologies manages its routine affairs as well as how well it operates its assets and liabilities.Some institutional investors establish a significant position in stocks such as Neurobiological Technologies in order to find ways to drive up its value. Retail investors, on the other hand, need to know that institutional holders can own millions of shares of Neurobiological Technologies, and when they decide to sell, the stock will often sell-off, which may instantly impact shareholders' value. So, traders who get in early or near the beginning of the institutional investor's buying cycle could potentially generate profits.
Neurobiological Technologies Workforce Comparison
Neurobiological Technologies is rated below average in number of employees category among its peers. The total workforce of Health Care industry is now estimated at about 241. Neurobiological Technologies claims roughly 4.0 in number of employees contributing just under 2% to equities under Health Care industry.
The company has Profit Margin (PM) of 0.74 %, which maeans that even a very small decline in it revenue will erase profits resulting in a net loss. This is way below average. Similarly, it shows Operating Margin (OM) of 0.77 %, which suggests for every 100 dollars of sales, it generated a net operating income of $0.77. Neurobiological Technologies Insider Trading
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Neurobiological Technologies insiders, such as employees or executives, is commonly permitted as long as it does not rely on Neurobiological Technologies' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, Neurobiological Technologies insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Highland Capital Management Lp over a month ago Acquisition by Highland Capital Management Lp of 20500 shares of Neurobiological Technologies at 2.58 subject to Rule 16b-3 | ||
Highland Capital Management Lp over three months ago Acquisition by Highland Capital Management Lp of 57000 shares of Neurobiological Technologies at 2.3882 subject to Rule 16b-3 | ||
Wasiewski Warren W over a year ago Neurobiological Technologies exotic insider transaction detected |
Neurobiological Technologies Notable Stakeholders
A Neurobiological Technologies stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Neurobiological Technologies often face trade-offs trying to please all of them. Neurobiological Technologies' stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Neurobiological Technologies' stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
| John Stuppin | Founder, Director, Chairman of Nominating and Corporate Governance Committee and Member of Special Committee | Profile | |
| Stephen Ferruolo | Sec | Profile |
About Neurobiological Technologies Management Performance
The success or failure of an entity such as Neurobiological Technologies often depends on how effective the management is. Neurobiological Technologies management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Neurobiological management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Neurobiological management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
Neurobiological Technologies, Inc. operates under a plan of liquidation and dissolution approved by stockholders in October 2009. The company was founded in 1987 and is based in Emeryville, California. Neurobiological Technologies operates under Biotechnology classification in the United States and is traded on OTC Exchange. It employs 4 people.
Neurobiological Technologies Workforce Analysis
Traditionally, organizations such as Neurobiological Technologies use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Neurobiological Technologies within its industry.Neurobiological Technologies Manpower Efficiency
Return on Neurobiological Technologies Manpower
| Revenue Per Employee | 1.5M | |
| Revenue Per Executive | 3M | |
| Net Income Per Employee | 1.2M | |
| Net Income Per Executive | 2.5M |
Complementary Tools for Neurobiological Stock analysis
When running Neurobiological Technologies' price analysis, check to measure Neurobiological Technologies' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Neurobiological Technologies is operating at the current time. Most of Neurobiological Technologies' value examination focuses on studying past and present price action to predict the probability of Neurobiological Technologies' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Neurobiological Technologies' price. Additionally, you may evaluate how the addition of Neurobiological Technologies to your portfolios can decrease your overall portfolio volatility.
| Commodity Channel Use Commodity Channel Index to analyze current equity momentum | |
| Price Exposure Probability Analyze equity upside and downside potential for a given time horizon across multiple markets | |
| Fundamentals Comparison Compare fundamentals across multiple equities to find investing opportunities |